Assessing Quality of Life and Patient-Reported Outcomes in Diabetic Macular Edema Treated With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Agents: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 26 October 2025
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95469
Abstract
Diabetic macular edema (DME) is a leading cause of vision impairment, with profound effects on patients’ quality of life (QoL). Anti-vascular endothelial growth factor (anti-VEGF) agents are the current standard of care, but their impact on patient-reported outcomes (PROMs) remains incompletely understood. We conducted a systematic review and meta-analysis of five randomized controlled trials (RCTs) and one cohort study involving 1,793 participants, evaluating the effects of anti-VEGF therapy compared with sham injections or laser therapy on QoL as measured by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Pooled analysis demonstrated a statistically significant improvement in composite QoL scores with anti-VEGF therapy (mean difference 3.11; 95% CI 1.89-4.33; p<0.00001), although the absolute magnitude of improvement was modest. Subgroup analysis revealed greater benefit compared with sham injections than with laser therapy, and long-term follow-up (24 months) showed more pronounced gains compared with shorter durations. Sensitivity analysis excluding the non-randomized study confirmed the robustness of these findings. While anti-VEGF therapy improves QoL in patients with DME, real-world barriers such as treatment burden, access, and cost may limit patient-perceived benefits. Future research should integrate patient-centered approaches to better capture the treatment impact beyond visual outcomes.Keywords
This publication has 31 references indexed in Scilit:
- Socioeconomic Cost of Diabetic Retinopathy and Therapy2017
- Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world settingDiabetes Research and Clinical Practice, 2016
- Diabetic Macular Edema: Options for Adjunct TherapyDrugs, 2015
- Changes in vision related quality of life in patients with diabetic macular edema: Ranibizumab or laser treatment?Journal of Diabetes and its Complications, 2015
- Vision-Related Function after Ranibizumab Treatment for Diabetic Macular EdemaOphthalmology, 2014
- Intravitreal Aflibercept for Diabetic Macular EdemaOphthalmology, 2014
- The RESTORE StudyOphthalmology, 2011
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Development of the 25-list-item National Eye Institute Visual Function QuestionnaireArchives of Ophthalmology (1950), 2001
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985